<code id='42691072D8'></code><style id='42691072D8'></style>
    • <acronym id='42691072D8'></acronym>
      <center id='42691072D8'><center id='42691072D8'><tfoot id='42691072D8'></tfoot></center><abbr id='42691072D8'><dir id='42691072D8'><tfoot id='42691072D8'></tfoot><noframes id='42691072D8'>

    • <optgroup id='42691072D8'><strike id='42691072D8'><sup id='42691072D8'></sup></strike><code id='42691072D8'></code></optgroup>
        1. <b id='42691072D8'><label id='42691072D8'><select id='42691072D8'><dt id='42691072D8'><span id='42691072D8'></span></dt></select></label></b><u id='42691072D8'></u>
          <i id='42691072D8'><strike id='42691072D8'><tt id='42691072D8'><pre id='42691072D8'></pre></tt></strike></i>

          
          WSS
          Cambridge: Biogen
          Ruby Wallau for STAT

          Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

          The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

          advertisement

          HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion